T/myeloid mixed-phenotype acute leukemia treated with venetoclax and decitabine: A case report
Sungwoo Park, Eun Jeong Jeong, Jung Hun Kang, Gyeong-Won Lee, Se-Il Go, Dong-Hyun Lee, Eun-Ha Koh
Sungwoo Park, Eun Jeong Jeong, Jung Hun Kang, Gyeong-Won Lee, Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Gyeongsang National University, Jinju 52727, South Korea
Se-Il Go, Department of Internal Medicine, Institute of Health Sciences, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon 52828, South Korea
Dong-Hyun Lee, Eun-Ha Koh, Department of Laboratory Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Gyeongsang National University, Jinju 52828, South Korea
Author contributions: Park S was involved in the conception and design of the study, analyzed the data, and wrote the article; Jeong EJ, Kang JH, Lee DH, Koh EH, and Go SI performed the treatment, acquired the data, and revised the manuscript; Lee GW was involved in the conception and design of the study, critically revised the manuscript for important intellectual content, and gave final approval for the version to be submitted.
Informed consent statement: The requirement for informed consent was waived because the analysis used completely anonymous data; consent was obtained before performing any medical investigation or the start of treatment as required.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Gyeong-Won Lee, MD, PhD, Professor, Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, 79 Gangnam-ro, Jinju-si, Gyeongsangnam-do 52727, South Korea. brightree@naver.com
Received: May 25, 2023
Peer-review started: May 25, 2023
First decision: June 15, 2023
Revised: July 24, 2023
Accepted: August 18, 2023
Article in press: August 18, 2023
Published online: September 16, 2023
